SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-17-008480
Filing Date
2017-11-08
Accepted
2017-11-08 07:30:03
Documents
54
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q syrs-20170930x10q.htm 10-Q 1891595
2 EX-31.1 syrs-20170930ex311e1de82.htm EX-31.1 10278
3 EX-31.2 syrs-20170930ex312ab8625.htm EX-31.2 10810
4 EX-32.1 syrs-20170930ex321b0ba72.htm EX-32.1 7467
5 EX-32.2 syrs-20170930ex32296cba3.htm EX-32.2 7490
  Complete submission text file 0001558370-17-008480.txt   5655700

Data Files

Seq Description Document Type Size
6 EX-101.INS syrs-20170930.xml EX-101.INS 1051684
7 EX-101.SCH syrs-20170930.xsd EX-101.SCH 32732
8 EX-101.CAL syrs-20170930_cal.xml EX-101.CAL 40289
9 EX-101.DEF syrs-20170930_def.xml EX-101.DEF 139151
10 EX-101.LAB syrs-20170930_lab.xml EX-101.LAB 370345
11 EX-101.PRE syrs-20170930_pre.xml EX-101.PRE 261521
Mailing Address 620 MEMORIAL DRIVE SUITE 300 CAMBRIDGE MA 02139
Business Address 620 MEMORIAL DRIVE SUITE 300 CAMBRIDGE MA 02139 617-744-1340
Syros Pharmaceuticals, Inc. (Filer) CIK: 0001556263 (see all company filings)

IRS No.: 453772460 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37813 | Film No.: 171185068
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences